The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

NAFDAC has uncovered counterfeit medicines and unregistered narcotics during its enforcement operation at the Idumota open ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session.